Access Vascular raises $3m for anti-clot PICC technology

Access Vascular raised more than $3 million from a consortium of new and existing investors that CEO Jim Biggins said should be sufficient to carry the company through a post-market clinical evaluation of its HyrdoPICC catheter and into the regulatory process for its next iteration. Biggins told MassDevice.com yesterday that the $3.4 million round was led by a “family office in the Boston area” that’s backed Access since its 2015 inception. “They’ve been supporting us since the beginning of the company and they helped price and lead this most recent round,” he told us, adding that half of the funding came from existing backers and the rest from new domestic and international investors. “I’m very grateful for the support of our existing and new investors. I think it says a lot about what we’re building here, great technology and a great team,” Biggins said during a telephone interview. “I think we’re really just scratching the surface with what the technology can do. “That money will be used to fund a rollout of the initial post-market use of the device,” he added, essentially “a limited commercial launch.” Biggins A veteran of medtech giants Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT), and later Ocular Therapeutix (NSDQ:OCUL) under serial entrepreneur and hydrogel pioneer Amar Sawhney, Biggins formed the Bedford, Mass.-based company after spending 18 months seeking ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Catheters Funding Roundup Vascular Wall Street Beat accessvascular Source Type: news